Abvc Biopharma, Inc. (ABVC) Institutional Ownership

Ownership Summary

Abvc Biopharma, Inc. (NASDAQ:ABVC) currently has 15 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• The collective stake of institutional investors in Abvc Biopharma moved to 3.4% in December 2025, a shift up from the 3.1% reported for September 2025.
• Quarterly data indicates a 15.56% shift in institutional share volume, and the annual owner count reflects an increase of 7.14%.
• Of these 15 institutional investors, 12 increased their holdings in Abvc Biopharma, while 1 of them reduced positions, and 2 investors maintained their exposure.
• The total number of shares held by institutions in Abvc Biopharma increased to 856.23K as of December 2025, a net change of up by 115.30K shares quarter on quarter, and up 447.00K shares year over year.
• VANGUARD GROUP INC's holding of 287.94K shares as of December 31, 2025 makes it the primary institutional investor in Abvc Biopharma, owning 1.15% of the stock.
• Among the most significant buyers of Abvc Biopharma during December 2025 were CITADEL ADVISORS LLC (39.88K), VANGUARD GROUP INC (20.49K), GEODE CAPITAL MANAGEMENT, LLC (14.55K), XTX Topco Ltd (11.26K), JANE STREET GROUP, LLC (10.87K).
• Leading sellers of Abvc Biopharma stock in December 2025 included SIMPLEX TRADING, LLC (912).
• The top 10 institutional holders of Abvc Biopharma for the quarter ending December 2025 included VANGUARD GROUP INC (287.94K), GEODE CAPITAL MANAGEMENT, LLC (202.37K), RENAISSANCE TECHNOLOGIES LLC (114.26K), STATE STREET CORP (72.80K), BlackRock, Inc. (56.44K), CITADEL ADVISORS LLC (55.54K), NORTHERN TRUST CORP (32.09K), XTX Topco Ltd (11.26K), JANE STREET GROUP, LLC (10.87K), MORGAN STANLEY (5.17K).